

6. Literatur

1. Ahlgren JD, Hill MC, et al.: Pancreatic cancer: Patterns, diagnosis and approaches to treatment, In Ahlgren JD, McDonald JS (eds): *Gastrointestinal Oncology* ; Philadelphia: Lippincott (1992); 197-207
2. Ames BN: Micronutrients prevent cancer and delay aging, *Toxicol Let* (1998); 102: 5-18
3. Arnold JC, Neubauer HJ, et al.: Improved tumor staging by diagnostic laparoscopy, *Z Gastroenterol* (1999); 37: 483-488
4. Arnold JC, Schneider ARJ, et al.: Laparoskopisches Tumorstaging bei gastrointestinalen Karzinomen: Bedeutung der internistischen Laparoskopie, *Z Gastroenterol* (2001); 39 (suppl.1): 19-23
5. Arnold R, Neuhaus C, et al.: Therapie endokriner gastroenteropankreatischer Tumoren mit dem Somatostatin-Analagon Octreotid, *Dtsch med Wschr* (1992); 117: 1067-1071
6. Arnold R, Frank M, et al.: Management of gastroenteropancreatic endocrine tumors: The place of somatostatin analogues, *Digestion* (1994); 55 (suppl.3): 107-113
7. Azria D, Ychou M, et al.: Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy, with 5-fluorouracil and cisplatin, *Pancreas* (2002); 25 (4): 360-365
8. Balkan J, Dogru-Abbasoglu S, et al.: Taurine has a protective effect against thioacetamide-induced liver cirrhosis by decreasing oxidative stress, *Hum Exp Toxicol* (2001); 20 (5): 251-254
9. Bauer W, Briner U, et al.: SMS201-995: A very potent and selective octapeptide analog of somatostatin with prolonged action, *Life Sci* (1982); 31: 1133-1140
10. Beauchamp C, Fridovich I: Superoxide Dismutase: Improved assays and an assay applicable to acrylamide gels, *Anal Biochem* (1971); 44 (1): 276-287
11. Bedrosian I, Sofia RD, et al.: Taurolidine, an analogue of the amino acid taurine, suppresses interleukin-1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells, *Cytokine* (1991); 3: 568-575
12. Borrello S, De-Leo ME, et al.: Defective gene expression of MnSOD in cancer cells, *Mol Aspects Med* (1993); 14: 253-258

13. Bousquet C, Puente E, et al.: Antiproliferative effect of somatostatin and analogs, *Chemotherapy* (2001) ; 47 (suppl.2): 30- 39
14. Bouvy ND, Marquet RL, et al.: Impact of gas(less) laparoscopy and laparotomy on peritoneal tumor growth and abdominal wall metastases, *Ann Sur* (1996); 224 (6): 694-701
15. Brambs HJ, Claussen CD: Pancreatic and ampullary carcinoma-ultrasound, computed tomography, magnetic resonance imaging and angiography, *Endoscopy* (1993); 25: 58
16. Brazeau P, Vale W, et al.: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone, *Science* (1973); 179: 77-79
17. Brunner T, Grabenbauer G, et al.: Adjuvant and neoadjuvant radiochemotherapy in ductal pancreatic carcinoma, *Strahlenther Onkol* (2000); 176: 265-273
18. Burch PA, Block M, et al.: Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: A north central cancer treatment group study, *Clin Cancer Res* (2000); 6: 3486-3492
19. Buscail L, Delesque N, et al.: Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogs: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2, *Proc Natl Acad Sci USA* (1994); 91: 2315-2319
20. Cai RZ, Szoke B, et al.: Synthesis and biological activity of highly potent octapeptide analogs of somatostatin, *Proc Natl Acad Sci USA* (1986); 83: 1896-1900
21. Calabresi P, Goulette FA, et al.: Taurolidene: Cytotoxic and mechanistic evaluation of a novel antineoplastic agent, *Cancer Res* (2001); 61(18): 6816-6821
22. Carriaga MT, Henson DE: Liver, gallbladder, extrahepatic bile ducts, and pancreas, *Cancer* (1995), 75 (1): 171-190
23. Carter JJ, Whelan RL: The immunologic consequences of laparoscopy in oncology, *Surg Oncol Clin N Am* (2001); 10(3): 655-677
24. Cascino S, Catalano V, et al.: Gastrointestinal cancer refractory to chemotherapy: A role for octreotide? *Chemotherapy* (2001); 47 (suppl.2): 127-133

25. Catheline JM, Turner R, et al.: The use of diagnostic laparoscopy supported by laparoscopic ultrasonography in the assessment of pancreatic cancer, *Surg Endosc* (1999); 13: 239-245
26. Cerutti PA: Oxy-radicals and cancer, *Lancet* (1994); 344: 862-863
27. Church SL, Grant JW, et al.: Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells, *Proc Natl Acad Sci USA* (1993); 90: 3113-3117
28. Compagno J, Oertel JE, et al.: Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinomas and cystadenomas): a clinico-pathologic study of 41 cases, *Am J Clin Pathol* (1978); 69: 537-580
29. Cooperman A, Kini S, et al.: Current surgical therapy for carcinoma of the pancreas, *J Clin Gastroenterol* (2000); 31: 107-113
30. Cullen JJ, Mitros FA, et al.: Expression of antioxidant enzymes in diseases of the human pancreas: Another link between chronic pancreatitis and pancreatic cancer, *Pancreas* (2003); 26: 23-27
31. Da Costa ML, Redmond HP, et al.: Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery, *J Surg Res* (2001); 101: 111-119
32. Dissemond J, Scharffetter-Kochanek K, et al.: Lipidperoxidation und enzymatische Antioxidantien, *Aktuel Ernaehr Med* (2000); 25: 192-198
33. Ebert M, Friess H, et al.: Role of octreotide in the treatment of pancreatic cancer, *Digestion* (1994); 55 (suppl.1): 48-51
34. Edge SB, Schmeig RE, et al.: Pancreas cancer resection outcome in american university centres in 1989-1990, *Cancer* (1993); 71: 3502-3508
35. Farrow B, Evers BM: Inflammation and the development of pancreatic cancer, *Surg Oncol* (2002); 10: 153-169
36. Fazeny B, Baur M, et al.: Octreotide combined with goserelin in the therapy of advanced pancreatic cancer-results of a pilot study and review of the literature, *J Cancer Res Clin Oncol* (1997); 123: 45-52
37. Feussner H, Kraemer SJM, et al.: Staging Laparoskopie, *Chirurg* (1997); 68: 201-209

38. Fisher WE, Muscarella P, et al.: Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide, *Surgery* (1996); 120: 234-241
39. Freeny PC: Pancreatic carcinoma: Imaging update 2001, *Dig Dis* (2001); 19: 37-46
40. Freeny, PC: Pancreatic carcinoma: What is the best imaging test? *Pancreatology* (2001); 1: 604-609
41. Friess H, Büchler M, et al.: Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer, *Pancreas* (1993); 8: 540-545
42. Geer RJ, Brennan MF: Prognostic indicators for survival after resection of pancreatic adenocarcinoma, *Am J Surg* (1993); 165: 68-72
43. Gillespie J, Poston GJ, et al.: Human pancreatic cancer cell lines do not express receptors for somatostatin, *Br J Cancer* (1992) ; 66: 483-487
44. Gitotti AW: Mechanisms of lipid peroxidation, *J Free Rad Biol Med* (1985); 1: 87-95
45. Gloor B, Todd KE, et al.: Diagnostic workup of patients with suspected pancreatic carcinoma, *Cancer* (1997); 79: 1780-1786
46. Goldstein DS, Lu ML, et al.: Inhibition of peritoneal tumor-cell implantation: Model for laparoscopic cancer surgery, *J Endourol* (1993); 7: 237-241
47. Gutt CN, Gessmann T, et al.: The impact of carbon dioxide and helium insufflation on experimental liver metastases, macrophages, and cell adhesion molecules, *Surg Endosc* (2003); 17:1628-1631
48. Gutt CN, Hollander D, et al.: Influence of laparoscopy and laparotomy on systemic and peritoneal T-lymphocytes in a rat model, *Int J Colorectal Dis* (2001); 16: 216-220
49. Gutt CN, Kim ZG, et al.: Impact of laparoscopic and conventional surgery on kupffer cells, tumor-associated CD44 expression, and intrahepatic tumor spread, *Arch Surg* (2002); 137: 1408-1412
50. Gutt CN, Schmandra TC: Portal venous flow during CO(2) pneumoperitoneum in the rat, *Surg Endosc* (1999); 13: 902-905
51. Hall PA, Lemoine NR: Models of pancreatic cancer, *Cancer Surv* (1993); 16: 135-154
52. Halliwell B, Gutteridge JMC: Role of free radicals and catalytic metal ions in human disease: An overview, *Meth Enzymol* (1989); 186: 1-85

53. Holzman MD, Reintgen KL, et al.: The role of laparoscopy in the management of suspected pancreatic and periampullary malignancies, *J Gastrointest Surg* (1997); 1: 236-244
54. Horrobin DF: Essential fatty acids, lipid peroxidation and cancer, in Horrobin DF (ed.): *w-6 Essential fatty acids*, New York, Wiley-Liss (1990): 351-378
55. Hubens G, Pauwels M, et al.: The influence of a pneumoperitoneum on the peritoneal implantation of free intraperitoneal colon cancer cells, *Surg Endosc* (1996); 10: 809-812
56. Hunt GC, Faigel DO: Assessment of EUS for diagnosing, staging and determining resectability of pancreatic cancer: A review, *Gastrointest Endosc* (2000); 55: 232- 237
57. Jacobi CA, Bonjer HJ, et al.: Oncologic implications of laparoscopic and open surgery, *Surg Endosc* (2002); 16: 441-445
58. Jacobi CA, Ordemann J, et al.: Inhibition of peritoneal tumor cell growth and implantation in laparoscopic surgery in a rat model, *Am J Surg* (1997); 174: 359-363
59. Jacobi CA, Peter FJ, et al.: New therapeutic strategies to avoid intra- and extraperitoneal metastases during laparoscopy: Results of a tumor model in the rat, *Dig Surg* (1999);16: 393-399
60. Jacobi CA, Sabat R, et al.: Pneumoperitoneum with carbon dioxide stimulates growth of malignant colonic cells, *Surgery* (1997); 121: 72-78
61. Jacobi CA, Sabat R, et al.: Peritoneale Installation von Taurolidin und Heparin zur Verhinderung von intraperitonealem Tumorwachstum und Trokarmetastasen bei laparoskopischen Operationen im Rattenmodell, *Langenbecks Arch Chir* (1997); 382 (suppl.1): 31-36
62. Jacobi CA, Wenger FA, et al.: Experimental study of the effect of intra-abdominal pressure during laparoscopy on tumour growth and port site metastasis, *Br J Surg* (1998); 85: 1419-1422
63. Jacobi CA, Wenger F, et al.: The impact of laparoscopy with carbon dioxide versus helium on immunologic function and tumor growth in a rat model, *Dig Surg* (1998); 15: 110-116
64. Jacobi CA, Wildbredt P, et al.: Influence of different gases and intraperitoneal instillation of antiadherent or cytotoxic agents on peritoneal tumor cell growth

- and implantation with laparoscopic surgery in a rat model, *Surg Endosc* (1999); 13: 1021-1025
65. Jacobi CA, Wildbredt P, et al.: Influence of intraperitoneal or intravenous application of taurolidine/heparin in laparoscopic surgery on peritoneal tumor growth, (1999) Data presented of the Third International Laparoscopic Physiology Conference, March 1999, New York, USA
 66. Jacobi CA, Wildbredt P, et al.: Influence of gases and intraperitoneal instillation of different agents in the prevention of metastases during laparoscopy, (1999) Data presented of the Third International Laparoscopic Physiology Conference, March 1999, New York, USA
 67. Janero DR: Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and and peroxidative tissue injury, *Free Radic Biol* (1990); 9: 515-540
 68. Jiang WG, Bryce RP, et al.: Inhibition of invasion and motility of human colon cancer cells by γ -linolenic-acid, *Br J Cancer* (1995); 71: 744-752
 69. Jimenez RE, Warshaw AL, et al.: Impact of laparoscopic staging in the treatment of pancreatic cancer, *Arch Surg* (2000); 135: 409-415
 70. Jorgensen JO, McCall JL, et al.: Port site seeding after laporoscopic ultrasonographic staging of pancreatic carcinoma, *Surgery* (1995);117: 118-119
 71. Kelly DM, Benjamin IS: Pancreatic Carcinoma, *Ann Oncol* (1995); 6: 19-28
 72. Kikutsuji T, Harada M, et al.: Expression of somatostatin receptor subtypes and growth inhibition in human exocrine pancreatic cancers, *J Hepatobiliary Pancreat Surg* (2000); 7: 496-503
 73. Köckerling F, Reymond MA, et al.: Fehler und Gefahren in der onkologischen laparoskopischen Chirurgie, *Chirurg* (1997); 68: 215-224
 74. Konukoglu D, lynem H, et al.: Antioxidant status in experimental peritonitis: Effects of alpha tocopherol and taurolin, *Pharmacol Res* (1999); 39: 247- 51
 75. Kurzawinski T, Deery A, et al.: Diagnostic value of cytology for biliary stricture, *Br J Surg* (1993); 80: 414-421
 76. Lamberts SWS, Uitterlinden P, et al.: Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995, *N Engl J Med* (1985); 313: 1576-1579

77. Lee SW, Southall J, et al.: Traumatic handling of the tumor independent of pneumoperitoneum increases port site implantation rate of colon cancer in a murin model, *Surg Endosc* (1998);12: 828-834
78. Link KH, Formentini A, et al.: Resection and radiochemotherapy of pancreatic cancer – the future? *Langenbeck's Arch Surg* (1998); 383: 134-144
79. Little D, Regan M, et al.: Perioperative immune modulation, *Surgery* (1993); 114: 87-91
80. Liu TZ, Stern A, et al.: Clastogenic factors: Biomarkers of oxidative stress of potential utility in clinical chemistry laboratory, *Ann Clin Lab Sci* (1999); 29: 134-139
81. Longnecker DS, Roebuck BD, et al.: Enhancemet of pancreatic carcinogenesis by a dietary unsaturated fat in rats treated with saline or N-nitroso(2-hydroxypropyl)(2-oxopropyl)amine, *J Natl Cancer Inst* (1985); 74: 219-222
82. Lowenfels AB, Maisonneuve P, et al.: Pancreatitis and the risk of pancreatic cancer, *N Engl J Med* (1993); 328: 1433-1437
83. Lowry OH, Rosebrough NJ, et al.: Protein measurement with the folin phenol reagent, *J Biol Chem* (1951); 193: 265-275
84. Mäkinen K, Loimas S et al.: Azaserine-induced rat pancreas tumor model with transplantable cultured cells, *Pancreas* (1998); 16: 160-164
85. McCourt M, Wang JH, et al.: Taurolidine inhibits tumor cell growth in vitro and in vivo, *Ann Surg Oncol* (2000); 7: 685-691
86. Meijers M, van Garderen-Hoetner A, et al.: Role of cholecystokinin in the development of BOP-induced pancreatic lesions in hamsters, *Carcinogenesis* (1990); 11: 2223-2226
87. Merchant N, Conlon K, et al.: Laparoscopic evaluation in pancreatic cancer, *Semin Surg Oncol* (1998); 15: 155-165
88. Meryn S: Pankreaskarzinom – Epidemiologie und Risikofaktoren, *Wien Klin Wochenschr* (1994); 106: 694-697
89. Mohr K: Octreotid , *Dtsch Med Wschr* (1995); 120: 1051-1052
90. Morohoshi T, Held G, Klopel G: Exocrine pancreatic tumors and their histological classification: A study based on 167 autopsy and 97 surgical cases, *Histopathology* (1983); 7: 645-61
91. Murr MM, Sarr MG, et al.: Pancreatic Cancer, *CA Cancer J Clin* (1994); 44: 304-318

92. Mutter D, Hajri A, et al.: Increased tumor growth and spread after laparoscopy vs laparotomy, *Surg Endosc* (1999); 13: 365-370
93. Neoptolemos JP, Kerr DJ, et al.: ESPAC-1 trial progress report : The european randomized adjuvant study comparing radiochemotherapy, 6 months chemotherapy and combination therapy versus observation in pancreatic cancer, *Digestion* (1997); 58: 570-577
94. Nduka CC, Monson JRT, et al.: Abdominal wall metastasis following laparoscopy, *Br J Surg* (1994); 81: 648-652
95. Neuhaus SJ, Texler M, et al.: Port-site metastases following laparoscopic surgery, *Br J Surg* (1998); 85: 735-741
96. Neuhaus SJ, Watson DI, et al.: Influence of gases on intraperitoneal immunity during laparoscopy in tumor-bearing rats, *World J Surg* (2000); 24: 1227-1231
97. Neuhaus SJ, Watson DI, et al.: Metabolic and immunologic consequences of laparoscopy with helium or carbon dioxide insufflation: a randomized clinical study, *ANZ J Surg* (2001); 71: 447-452
98. Nieveen van Dijkum EJM, Obertop LTh van, et al.: Port site metastases following diagnostic laparoscopy, *Br J Surg* (1996); 83: 1793-1794
99. Nold R, Frank M, et al.: Kombinierte Behandlung metastasierter endokriner Tumoren des GIT mit Octreotid und Interferon-Alpha, *Z Gastroenterol* (1994); 32: 193-197
100. Ohkawa H, Ohishi N, et al.: Assay for lipid peroxides in animal tissue by thiobarbituric acid reaction, *Anal Biochem* (1979); 95: 351-358
101. Ohlenschläger G: *Freie Radikale, oxidativer Stress und Antioxidantien*, Köln: Reglin Verlag (1995);
102. Ozawa F, Friess H, et al.: Treatment of pancreatic cancer: the role of surgery, *Dig Dis* (2001); 19: 47-56
103. Packer L: Oxidants, antioxidant nutrients and the athlete, *J Sports Sci* (1997); 15: 353-363
104. Paglia DE, Valentine WN: Studies on the quantitative and qualitative characterization of erythrocytes glutathione peroxidase, *J Lab Clin Med* (1967); 29: 143-148
105. Paolucci V, Schaeff B, et al.: Tumor seeding following laparoscopy: international survey, *World J Surg* (1999); 23: 989-997

106. Patel YC, Greenwood MT, et al.: The somatostatin receptor family, *Life Sci* (1995); 57: 1249-1265
107. Paz-Bouza JI, Redding TW, et al.: Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone, *Proc Natl Acad Sci USA* (1987); 84: 1112-1116
108. Périssat J, Collet D, et al.: Advances in Laparoscopic Surgery, *Digestion* (1998); 59: 606-618
109. Permert J, Hafström L, et al.: A systematic overview of chemotherapy effects in pancreatic cancer, *Acta Oncol* (2001); 40: 361-370
110. Pernick NL, Sarkar FH, et al.: Clinicopathologic analysis of pancreatic adenocarcinoma in african americans and caucasians, *Pancreas* (2003); 26: 28-32
111. Podda M, Traber MG, et al.: UV-irradiation depletes antioxidants and causes oxidative damage in a model of human skin, *Free Radic Biol Med* (1998); 24: 55-65
112. Pollak MN, Schally AV: Mechanisms of antineoplastic action of somatostatin analogs, *Proc Soc Exp Biol Med* (1998); 217: 143-152
113. Pour PM, Krüger FW, et al.: Cancer of the pancreas induced in the syrian golden hamster, *Am J Pathol* (1974); 76: 349-358
114. Pour PM, Runge RG, et al.: Current knowledge of pancreatic carcinogenesis in the hamster and its relevance to the human disease, *Cancer* (1981); 47: 1573-1587
115. Qin Y, Ertl T, et al.: Somatostatin analog RC-160 inhibits growth of CFPAC-1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate, *Int J Cancer* (1995); 60: 694-700
116. Raynor K, Murphy WA, et al.: Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides, *Mol Pharmacol* (1993); 8: 88-97
117. Raynor K, O'Carroll AM, et al.: Characterization of cloned somatostatin receptors SSTR4 and SSTR5, *Mol Pharmacol* (1993); 44: 385-392
118. Reddy KR, Levi J, et al.: Experience with staging laparoscopy in pancreatic malignancy, *Gastrointest Endosc* (1999); 49: 498-503
119. Redmond HP, Watson WG, et al.: Immune function in patients undergoing open vs laparoscopic cholecystectomy, *Arch Surg* (1994); 129: 1240-1246

120. Reichlin S: Somatostatin, *N Engl J Med* (1983); 309: 1495-1501
121. Reymond MA, Schneider C, et al.: Pathogenese von Impfmetastasen nach Laparoskopie, *Zentralbl Chir* (1997); 122: 387-394
122. Reymond MA, Wittekind CH, et al.: The incidence of port-site metastases might be reduced, *Surg Endosc* (1997); 11: 902-906
123. Reznek RH, Staphens DH: The staging of pancreatic adenocarcinoma, *Clin Radiol* (1993); 47: 373-381
124. Ridwelski K, Meyer F: Current opinion for palliative treatment in patients with pancreatic cancer, *Dig Dis* (2001); 19: 63-75
125. Ridwelski K, Meyer F, et al.: Prognostic parameters determining survival in pancreatic carcinoma and, in particular, after palliative treatment, *Dig Dis* (2001); 19: 85-92
126. Rivera JA, Graeme-Cook F, et al.: A rat model of pancreatic ductal adenocarcinoma: targeting chemical carcinogens, *Surgery* (1997); 122: 82-90
127. Rosenberg L: Pancreatic cancer: Does octreotide offer any promise? *Chemotherapy* (2001); 47 (suppl.2): 134-149
128. Rosenberg L, Barkun AN, et al.: Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas, *Cancer* (1995); 75: 23-28
129. Rosman C, Westerveld GJ, et al.: Effect of intraperitoneal antimicrobials on the concentration of bacteria, endotoxine and tumor necrosis factor in abdominal fluid and plasma in rats, *Eur Surg Res* (1996); 28: 351-360
130. Rosman C, Westerveld GJ, et al.: Local treatment of generalised peritonitis in rats; Effects on bacteria, endotoxin and mortality, *Eur J Surg* (1999); 165: 1072-1079
131. Santoro E, Carlini M, et al.: Laparoscopic pancreatic surgery: Indications, techniques and preliminary results, *Hepato Gastroenterol* (1999); 46: 1174-1180
132. Scarpignato C, Pelosini I: Somatostatin analogs for cancer treatment and diagnosis: An overview, *Chemotherapy* (2001); 47 (suppl.2): 1-29
133. Schally AV, Szepeshazi K, et al.: Antitumor effects of analogs of somatostatin and antagonists of bombesin/GRP in experimental models of pancreatic cancer, *Int J Pancreatol* (1994); 16: 246-249
134. Schäfer M, Mülhaupt B, et al.: Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis, *Ann Surg* (2002); 236: 137-148

135. Schlumpf R, Schöb O, et al.: Chirurgie des malignen Verschlussikterus: laparoskopische Operation – die Zukunft? Schweiz Med Wochenschr (1997); 127: 834-838
136. Schöfl R: Pankreaskarzinom – Diagnose und Screening – endoskopische Therapie, Wien Klin Wochenschr (1994); 106: 698-700
137. Schneider G, Lersch C, et al.: Karzinogenese des Pankreaskarzinoms, Chirurg (2003); 74: 165-170
138. Sies H: Introductory remarks. In: Sies H (ed): Oxidative Stress: Oxidants and Antioxidants, New York: Academic Press (1991);
139. Simon B, Printz H: Epidemiological trends in pancreatic neoplasias, Dig Dis (2001); 19: 6-14
140. Siriwardena A, Samarji WN: Cutaneous tumour seeding from a previously undiagnosed pancreatic carcinoma after laparoscopic cholecystectomy, Ann Coll Surg Engl (1993); 75: 199-200
141. Standop J, Schneider MB, et al.: Experimental animal models in pancreatic carcinogenesis: lessons for human pancreatic cancer, Dig Dis (2001); 19: 24-31
142. Staubach KH: Adjuvant therapy of peritonitis with taurolidine. Modulation of mediator liberation, Langenbecks Arch Chir (1997); 382 (suppl.1): 26- 30
143. Stöckmann F: Somatostatin und Octreotid in der Therapie gastrointestinaler Erkrankungen, Z Gastroenterol Verh (1991); 26: 166-170
144. Szepeshazi K, Lapis K, et al.: Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-Fluorouracil on pancreatic cancer in hamsters, Int J Cancer (1991); 49: 260-266
145. Szepeshazi K, Schally A, et al.: Inhibitory effect of Bombesin/Gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters, Cancer research (1991); 51: 5980-5986
146. Targarona EM, Pera M, et al.: Laparoscopic treatment of pancreatic disorders: Diagnosis and staging, palliation of cancer and treatment of pancreatic pseudocysts, Int Surg (1996); 81: 1-5
147. Thomas WJ, Thomas DL, et al.: The role of oxygen-derived free radicals and nitric oxide in cytokine-induced antiproliferation of pancreatic cancer cells, Pancreas (2002); 24: 161-168

148. Thompson D, Arregui M: Role of laparoscopic ultrasound in cancer management, *Semin Surg Oncol* (1998); 15: 16-175
149. Tseng LNL, Berends FJ, et al.: Port-site metastases: Impact of local tissue trauma and gas leakage, *Surg Endosc* (1998); 12: 1377-1380
150. Van Driel B, Van Noorden C: Oxygen insensitivity of the histochemical assay of glucose-6-phosphate dehydrogenase activity for the discrimination between nonmalignant and malignant cells, *J Histochem Cytochem* (1999); 47: 575- 582
151. Vidal C, Raully I, et al.: Up-regulation of somatostatin receptors by epidermal growth factor and gastrin in pancreatic cancer cells, *Molecular Pharmacology* (1994); 45: 97-104
152. Vöhringer ML, Becker TW, et al.: Synergistic DNA damaging effects of MDA/Cu in PM2 DNA and in human fibroblasts, *Tox Lett* (1998); 94: 159-166
153. Wanebo HJ, Vezeridis MP: Pancreatic Carcinoma: An Overview, *Semin Surg Oncol* (1995); 11: 168-180
154. Warshaw AL, Fernandez-del Castillo C: Pancreatic Carcinoma, *N Engl J Med* (1992); 326: 455-465
155. Watanapa P, Williamson RCN: Experimental pancreatic hyperplasia and neoplasia: Effects of dietary and surgical manipulation, *Br J Cancer* (1993); 67: 877-84
156. Watson DI: Abdominal wall metastasis after laparoscopic gastroenterostomy, *Med J Aust* (1995); 163: 106-107
157. Watson RW, Redmond HP, et al.: Taurolidine, an antilipopolsaccharide agent, has immunoregulatory properties that are mediated by the amino acid taurine, *J Leukoc Biol* (1995); 58: 299-306
158. Welzel TM, Vick C, et al.: Pankreaskarzinom: Präzisierung der Diagnostik zur weiteren Therapieplanung, *Chirurg* (2003); 74: 171-182
159. Wenger FA, Jacobi CA, et al.: The impact of laparoscopic biopsy of pancreatic lymph nodes with helium and carbon dioxide on port site and liver metastasis in BOP-induced pancreatic cancer in hamster, *Clin Exp Metast* (2000); 18: 11-14
160. Wenger FA, Jacobi CA et al.: Tumor size and lymph-node status in pancreatic carcinoma – is there a correlation to the preoperative immune function? *Langenbeck's Arch Surg* (1999); 384: 473-478
161. Wenger FA, Jacobi CA, et al.: Hormontherapie des postoperativ rezidivierten Pankreaskarzinoms mit Octreotid und Tamoxifen, *Chirurg* (1999); 70: 694-699

162. Wenger FA, Jacobi CA, et al.: Does dietary alpha-linolenic acid promote liver metastasis of pancreatic carcinoma initiated by BOP in syrian hamsters? *Ann Nutr Metabol* (1999); 43: 121-126
163. Wenger FA, Kilian M, et al.: Effects of octreotide on liver metastasis and intrametastatic lipid peroxidation in experimental pancreatic cancer, *Oncology* (2001); 60: 282-288
164. Wenger FA, Kilian M, et al.: Does alpha-linolenic acid in combination with linoleic acid influence liver metastasis and hepatic lipid peroxidation in BOP-induced pancreatic cancer in syrian hamsters? *Prostagland Leukot Essent Fatty Acids* (2000); 62: 329-334
165. Wenger FA, Peter F, et al.: Prognosis factors in carcinoma of the head of the pancreas, *Dig Surg* (2000); 17: 29-35
166. Westphal S, Kalthoff H: Apoptosis: Targets in Pancreatic Cancer, *Mol Cancer* (2003); 2: 6
167. Whelan RL, Franklin M, et al.: Postoperative cell mediated immune response is better preserved after laparoscopic vs open colorectal resection in human, *Surg Endosc* (2003); 17: 972-978
168. Wiernik PH: Current status of and future prospects for the medical management of adenocarcinoma of the exocrine pancreas, *J Clin Gastroenterol* (2000); 30: 357-363
169. Yang MH, Schaich KM: Factors effecting DNA damage caused by lipid hydroperoxides and aldehydes, *Free Radic Biol Med* (1996); 20: 225-236
170. Y eo CJ, Cameron JL: Pancreatic Cancer, *Curr Probl Surg* (1999); 36: 67-152